Leslie Stolz
Consejero General en VERVE THERAPEUTICS, INC. .
Cargos activos de Leslie Stolz
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
VERVE THERAPEUTICS, INC. | Consejero General | 01/06/2019 | - |
Historial de carrera de Leslie Stolz
Antiguos cargos conocidos de Leslie Stolz.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | 01/01/2018 |
Formación de Leslie Stolz.
Duke University | Doctorate Degree |
Villanova University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
General Counsel | 1 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
VERVE THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Leslie Stolz
- Experiencia